Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s stock price reached a new 52-week high during trading on Wednesday . TD Cowen started coverage on Dyne Therapeutics in a research note on Friday, June 26th. Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. Also, Director Jason P. Rhodes sold 480,240 shares of Dyne Therapeutics stock in a transaction dated Monday, July 6th. See AlsoReceive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.